Transplanting hepatitis B surface antigen–positive livers in the United States: Outcomes and opportunities
American Journal of Transplantation · 2023
DOI: 10.1016/j.ajt.2023.04.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Transplantation, 2023. Verfasst von Anshul Bhatnagar und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Liver Transplantation, Hepatitis B. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Livers from donors with positive hepatitis B surface antigens (HBsAg+) have been used to expand the donor pool; however, outcome data are limited. We aim to evaluate survival following liver transplant (LT) from HBsAg+ donors. Using the United Network for Organ Sharing registry, we identified HBsAg+ donors used for LT from 2009 to 2020. We used Kaplan-Meier survival and Cox proportional hazards regression to compare post-LT survival in hepatitis B virus-negative recipients who utilized HBsAg+ donors to propensity-matched cohorts who utilized other types of donors. From 2009-2020, 70 patients received HBsAg+ livers, and 58 of them did not carry a diagnosis of chronic hepatitis B virus. The 1- and 3-year post-LT survival for hepatitis B virus-negative patients who received livers from HBsAg+ donors were 96.6% and 91.4%, respectively, with no statistical differences compared with patients who received livers from hepatitis C virus viremic donors (96.5%/93.0%, P = .961/.427), donation after cardiac death donors (93.0%/86.0%, P = .651/.598), average-risk donors (89.5%/86.0%, P = 0.264/0.617), and a combination of extended-criteria donors, including donation after cardiac death, donor age over 70, and graft with greater than 30% steatosis (93.0%/91.2%, P = .621/.785). Recipients of HBsAg+ livers have similar post-LT survival compared with those receiving other types of grafts. Increasing the utilization of HBsAg+ livers could safely expand the donor pool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Memorial Hermann Hospital The Woodlands, Spring, Texas, USA.
- Department of Medicine, State University of New York (SUNY) Downstate, Health Sciences University, Brooklyn, New York, USA.
- Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut.
- Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA.
- Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Bhatnagar, A., Prakash, S., Lymberopoulos, P., Goff, C., Shaikh, A., Kim, D., Ahmed, A., Berg, C., Naggie, S., Kanwal, F., Cholankeril, G., & Lee, T. H. (2023). Transplanting hepatitis B surface antigen–positive livers in the United States: Outcomes and opportunities. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2023.04.024
Vancouver
Bhatnagar A, Prakash S, Lymberopoulos P, Goff C, Shaikh A, Kim D, et al. Transplanting hepatitis B surface antigen–positive livers in the United States: Outcomes and opportunities. American Journal of Transplantation. 2023. doi:10.1016/j.ajt.2023.04.024
BibTeX
@article{Bhatnagar2023,
author = {Bhatnagar, Anshul and Prakash, Sameer and Lymberopoulos, Peter and Goff, Cameron and Shaikh, Anjiya and Kim, Donghee and Ahmed, Aijaz and Berg, Carl and Naggie, Susanna and Kanwal, Fasiha and Cholankeril, George and Lee, Tzu-Hao},
title = {Transplanting hepatitis B surface antigen–positive livers in the United States: Outcomes and opportunities},
journal = {American Journal of Transplantation},
year = {2023},
doi = {10.1016/j.ajt.2023.04.024}
}
EUVIMED